Cite
HARVARD Citation
Sutter, G. et al. (2022). Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure–response modelling and simulation. British journal of clinical pharmacology. 88 (2), pp. 734-741. [Online].